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A protocol for a randomized controlled trial
investigating the safety and cost-
effectiveness of outpatient total hip
arthroplasty
Bryn O. Zomar1,2, Jacquelyn D. Marsh1,2, Brent A. Lanting2,3,4 and Dianne M. Bryant1,2*
Abstract
Background: A significant proportion of the overall cost of total hip arthroplasty (THA) results from the inpatient
hospital stay following the procedure. Considering the substantial and increasing number of these procedures
performed annually, shifting to an outpatient model of care where the patient is discharged home the same day as
their surgery represents a potential for significant cost savings. The potential significant impact of an outpatient
care model on constrained healthcare budgets and lack of high-quality evidence regarding its effectiveness
warrants a rigorous comparative trial. The purpose of this prospective, randomized controlled trial is to evaluate
outpatient care pathways for THA. Specifically, our objectives are to compare the rate of serious adverse events and
estimate the cost-effectiveness of outpatient compared to standard inpatient THA.
Methods: We will include patients undergoing primary THA whom have an American Society of Anaesthetists
status equal to or less than three, live within a 60-min driving distance of the institution and have an adult to
accompany them home postoperatively and stay with them overnight. Consenting patients will be randomized to
be discharged on the same day as surgery, as outpatients, or as inpatients according to standard of care (minimum
of one night in hospital) using a modified Zelen consent model. The primary outcome measure is the incidence of
serious adverse events at 30 days postoperative. Participants and their caregivers will complete secondary outcomes
measures at each follow-up visit including patient-reported outcome measures and self-reported cost
questionnaires.
Discussion: This protocol is the first randomized trial to use blinding to evaluate outpatient THA compared to
standard overnight stay and first to prospectively perform a full economic evaluation. It is also the first adequately
powered trial to prospectively assess the safety of outpatient THA. Successful completion of this study could have
the potential to provide clinical evidence for the role of outpatient THA in current practice.
Trial registration: This study was retrospectively registered on ClinicalTrials.gov (NCT03026764) on March 9th, 2016.
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Background
Osteoarthritis (OA) is a leading cause of disability and
reduced quality of life, presenting a substantial, growing
burden to patients and the healthcare system [1]. Total
hip arthroplasty (THA) is an established, effective inter-
vention for advanced OA. The prevalence of hip OA is
rapidly increasing, resulting in a rising demand for care.
The number of THA procedures is projected to grow by
71% between 2014 and 2030 in the US [2]. Currently,
THA, along with total knee arthroplasty (TKA), have a
significant impact on healthcare budgets, costing ap-
proximately $1.2 billion in annual spending in Canada
[3]. These staggering numbers highlight the critical need
to improve care delivery.
A significant proportion of the overall cost of joint re-
placement results from the inpatient hospital stay fol-
lowing the procedure. Historically, the standard
procedure following THA required an inpatient hospital
stay of two and a half to 3 weeks, however the introduc-
tion of less invasive surgical techniques, improved med-
ical and analgesia management and comprehensive
rehabilitation have enabled shorter inpatient stays.
Today, the median inpatient stay following THA is 3
days in Canada [3]. A desire for greater autonomy by the
patients as well as patients wanting early mobilization to
accelerate recovery and return to activities has led some
clinicians to consider an outpatient arthroplasty pro-
gram. The proposed benefits of outpatient arthroplasty
include similar patient outcomes with significantly lower
hospital costs, and improved patient satisfaction, inde-
pendence, and autonomy. However, there is a lack of
high-quality evidence comparing clinical outcomes of
outpatient to inpatient arthroplasty models of care.
A retrospective analysis of over 50,000 THA and TKA
procedures found no differences in 30-day major complica-
tions or readmissions among patients with a zero to two-
day hospital stay compared to those discharged on day
three or four postoperative [4]. Small cohort studies [5–8]
suggest lower costs for outpatients and improved patient
satisfaction but have inherent biases as they are limited to
carefully selected patients in privatized health systems.
It is estimated that up to 20% of the overall cost of
THA can be attributed to the inpatient stay in hospital
at our institution [9]. By discharging patients as outpa-
tients, it could be possible to have substantial savings.
Although these preliminary calculations are encouraging,
it is not sufficient to effect change solely to achieve cost
control, without consideration of safety, effectiveness
and patient satisfaction. Further, it is unknown whether
the financial savings will be outweighed by additional
postoperative costs, increased readmissions or decreased
quality of care. A full economic evaluation that simul-
taneously evaluates cost and effectiveness is crucial prior
to implementation. The lack of high-quality evidence
regarding its effectiveness warrants a rigorous compara-
tive trial.
The purpose of this study is to evaluate outpatient care
pathways for THA. Specifically, our objectives are to
compare the rate of serious adverse events and estimate
the cost-effectiveness of outpatient compared to stand-




Patients will be recruited from two orthopaedic centers
in Canada (London Health Science’s University Hospital,
London ON and St. Michael’s Hospital, Toronto ON).
The surgeons will screen potential participants in their
clinics and provide an overview of the research study
(Fig. 1).
Eligibility criteria
We will include patients undergoing primary THA. Eli-
gible patients will have an American Society of Anesthe-
tists (ASA) status equivalent or less than three, the ability
to read and understand English, live within a 60min com-
mute distance of the institution, have access to a phone,
and sufficient caregiver support. We will exclude patients
with a history of anesthesia related complications, narcotic
dependency, anaphylaxis to penicillin, significant psycho-
social issues that influence safety, or cognitive issues that
preclude the ability to understand instructions. We will
also exclude patients whom have fibromyalgia, are skelet-
ally immature, have an active or suspected latent infection
in or about the joint, bone stock inadequate for support or
fixation of the prosthesis, are unable to go to their home
after surgery, have neuromotor conditions, significant pain
management issues or obesity that significantly impacts
their ability to mobilize (Table 1).
Interventions
All patients will undergo a primary unilateral THA. All
THA procedures will be performed using a direct anterior
surgical approach according to the surgeon’s standard of
care. The specific surgical pathway details (anesthetic, im-
plants, etc.) will not be standardized for this study to main-
tain generalizability.
Both inpatient and outpatient care models begin with
comprehensive preoperative patient education to equip
the patient with a reasonable set of goals and expecta-
tions about their surgery, medications, pain management
and rehabilitation. Immediately following surgery, the
primary goals are to treat pain, nausea and hypovolemia.
The combination of this early rehabilitation program,
with a muscle sparing technique, is vital to the rapid re-
covery process. The surgical technique minimizes blood
loss, provides a stable construct to facilitate immediate
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weightbearing, minimizes soft tissue trauma and in-
cludes a peri-articular injection. Home-based physical
therapy should begin immediately, with a focus on
ambulation.
Perioperative care and discharge protocols will be
similar for both care models. Standard discharge criteria
includes: ability to use required gait aids, appropriate
pain control, control or absence of nausea and vomiting,
hemostasis at the surgical wound, hemodynamically
stable with appropriate laboratory values, alert and ori-
ented, able to use the bathroom, meets the hospital
standard targets from physiotherapy for discharge, given
take-home medications, and in the company of a care-
giver. Potential complications are also discussed so the
patient understands the normal course of recovery as
well as signs or symptoms that may be cause for concern
and additional consultation.
Patients randomized to inpatient
Patients allocated to the inpatient group will be dis-
charged home according to standard protocol at each
site (typically one to 4 days postoperative).
Patients randomized to outpatient
Patients allocated to the outpatient group will be discharged
home on the same day as the procedure. These patients will
receive an additional physiotherapy session prior to surgery
where they are instructed to practice certain skills such as
bed transfer, cane/crutches use and gait training.
Fig. 1 Participant flow through the study
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Outcomes
We will collect outcome data preoperatively and at
follow-up visits at discharge, 2 weeks, 6 weeks and 3
months postoperative, which is in keeping with usual
practice patterns. We will record anaesthesia and surgi-
cal time and blood loss for each procedure and demo-
graphic information including date of birth, sex, height,
weight, smoking status, and comorbidities.
Primary outcome
Given that the primary concern with sending patients
home earlier than usual is an increase in the number or
severity of early post-operative complications, our primary
outcome is any serious adverse event within the first 30
days postoperative. A serious adverse event is defined as
any untoward medical occurrence that results in death, is
life-threatening, requires inpatient hospitalization or
causes prolongation of existing hospitalization, results in
persistent or significant disability or incapacity, or requires
intervention to prevent permanent impairment or damage
[10–12].
Secondary outcomes
Our secondary outcomes include patient-reported satis-
faction, health-related quality of life (HRQOL), function,
pain, and caregiver assistance. Patients will be asked to
rate satisfaction with pain control, safety and quality of
care on either a 100-mm visual analogue scale (VAS)
with a score of 100 representing the highest possible sat-
isfaction, or on a five to seven-point ordinal scale (com-
pletely satisfied to completely unsatisfied).
We will measure HRQOL using the Western Ontario
and McMaster Universities Osteoarthritis Index
(WOMAC), which includes three arthritis-specific do-
mains of pain, stiffness and physical function. It has
demonstrated content, cross-sectional and construct
validity, good internal consistency reliability and moder-
ate to high test retest reliability in patients undergoing
THA and TKA [13]. To measure function, we will use
the Harris Hip Score (HHS) [14]; a valid and reliable ob-
jective functional measure completed by the surgeon.
We will measure general health using the 12-Item Short
Form Health Survey (SF-12v2) and the European Quality
of Life Scale (EQ-5D). The SF-12 evaluates limitations
on physical and social activities, activities of daily living,
pain, mental health and well-being, and perceptions of
health and is valid, reliable, and responsive in patients
with arthritis [15]. The EQ-5D index includes domains
of mobility, self-care, usual activities, pain, anxiety and
depression and has good test retest reliability and cross-
sectional construct validity in patients with arthritis [16].
We will measure pain using a self-administered Numeric
Pain Rating Scale (Pain NRS), ranging from 0 (no pain)
to 10 (worst). We will measure the level of assistance
provided by the caregiver throughout the recovery
period using the Caregiver Assistance Scale (CAS) [17]
and Caregiver Strain Index (CSI) [18].
Cost
We will ask patients to report any calls to the surgeon’s
office, the on-call resident, the orthopaedic outpatient
clinic, emergency room visits or hospitalizations for the
first 2 weeks postoperative. Patients will also complete a
healthcare resource use diary at each follow-up. The
diary includes information on emergency room visits,
hospitalizations, family doctor, specialist, healthcare pro-
fessional or outpatient clinic visits, tests, procedures, and
prescription or over-the-counter medications and any
other miscellaneous costs related to their joint replace-
ment. We will also record employment status and time-
off paid employment, homemaking or volunteer activ-
ities, for both patients and caregivers.
Table 1 Eligibility Criteria
Inclusion Criteria Exclusion Criteria
1. Primary THA 1. Fibromyalgia
2. ASA status ≤3 2. Skeletally immature
3. Ability to read and understand English 3. Cognitive or neuromotor conditions
4. Live within 60-min commute distance of hospital 4. Bone stock inadequate for support or fixation of prosthesis
5. Home/cell phone access 5. Unable to go to their home after surgery
6. An adult to accompany patient home postoperatively 6. Active or suspected latent infection in or about the joint
7. Significant pain management issues
8. Patient/family history of anesthesia related complication(s)
9. Obesity that significantly impacts the patient’s ability to mobilize
10. Anaphylaxis to penicillin
11. Significant psycho/social issues that would prevent the patient
from managing at home safely
12. Narcotic dependency
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We will obtain surgical procedure costs from our insti-
tutions’ case costing department. The unit costs for add-
itional resource use following surgery can be found in
provincial fee schedules and drug benefit formularies.
The average Canadian wage reported by Statistics
Canada will be applied to place a monetary figure on
time off paid employment, for both patients and their
caregivers and the current value of minimum wage in
the province of Ontario to account for lost time for
those who were retired, as well as time away from volun-
teer or home making activities.
The total cost will be determined by multiplying the
quantity of resource use by the corresponding unit cost,
summing the total cost over each follow up interval, and
then calculating the mean cost at each follow-up time
point, as well as an overall mean cost for the entire study
period.
Participant timeline
Patients will be screened and consent obtained at the
time of booking for surgery and baseline assessments
will occur at the preoperative visit within 3 months of
surgery. On the day of discharge from hospital, we will
obtain a pain score from participants and provide them
with a daily diary to record costs for the first 2 weeks.
Postoperatively, participants will be seen at 2 weeks, 6
weeks and 3 months for follow-up.
We will ask caregivers to complete questionnaires pre-
operatively and at 2 weeks postoperatively (Table 2).
Recruitment
Patients presenting to the clinic will first be booked for
THA by their surgeon. The surgeon will then assess
whether the patient is eligible for possible outpatient dis-
charge and will broadly discuss the study with the pa-
tient. The surgeon will then ask if the patient is
interested in hearing more about the study and whether
the research assistant may contact them with further in-
formation. Once patient approval is received, the patient
is contacted by the research assistant with more infor-
mation. All patients will be given the necessary time to
consider their participation in the study and to provide
informed consent if willing to participate.
Randomization
Concealment mechanism/implementation
Potential participants will be initially screened by their
treating surgeon and approached for participation by the
research assistant. To reduce selection bias, patients are
randomized into group using a stratified and blocked
scheme after eligibility has been fully determined. The
Table 2 Participant Timeline
Assessments Appointment
Baseline Discharge 2 weeks 6 weeks 3months
Demographics X – – – –
Charlson Comorbidity Index X – – – –
Self-Efficacy X – – – –
Pain Catastrophizing Scale X – – – –
Expectation Questionnaire: Preop X – – – –
Surgical Information Form – X – – –
Patient Flow – X – – –
Pain NRS X X X X X
SF-12v2 X – X X X
EQ-5D-5L X – – X X
WOMAC X – – – X
HHS X – – – X
Adverse Event Form – X X X X
Patient Satisfaction – – X – –
Daily Diary – – X – –
Patient Satisfaction and Expectations – – X X X
Cost Questionnaire – – X X X
Caregiver Demographics X – – – –
Caregiver Assistance Scale X – X – –
Caregiver Strain Index X – X – –
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research assistant will confirm their eligibility and, after
obtaining consent, will enter the patient’s date of birth
and whether they’ve had previous experience with THA
before randomizing the patient via a web-based
randomization system to inpatient or outpatient.
Allocation (sequence generation)
All participants will be randomized by the research as-
sistant using a 1:1 ratio for inpatient to outpatient.
Randomization will be stratified by surgeon and previous
experience with THA (had a THA on the contralateral
limb or were the caregiver for someone whom had a
THA). All patients will be analyzed according to the
treatment group as assigned regardless of when they
were discharged.
Blinding
To reduce detection bias, patients will be unaware that
they were randomly assigned to a discharge plan and re-
main blinded to the presence of a comparison group
until they reach the end of the study. Participants are
kept blinded to group allocation using a modified Zelen
consent model [19]. In this design, eligible patients are
randomized to the intervention prior to providing con-
sent to minimize the risk of bias associated with know-
ledge of the alternative intervention. We posit that
patients with a bias for inpatient care who are random-
ized to the outpatient group may be more likely to re-
turn to seek additional care significantly biasing costs.
Alternatively, patients with a strong preference for out-
patient care who are randomized to the inpatient group
may bias measures of satisfaction. Thus, patients are
asked to consent to participation in a research study
evaluating the outcomes and costs associated with pa-
tients undergoing THA; they are not told about
randomization, the existence of an alternative group, or
the between-groups objectives. At the end of the study,
all patients are informed about the deception and asked
to consent to having their data used for analysis.
As data collection occurs on the day of discharge from
the hospital, it is not possible to blind the research assist-
ant responsible for collecting patient-reported outcomes,
however since outcomes are patient-reported, we do not
expect an increase in the risk of detection bias. We are
also unable to blind investigators to group allocation.
Sample size
A retrospective analysis of over 50,000 THA and TKA
procedures found no differences in 30-day major com-
plications or readmissions among patients with a zero to
two-day hospital stay compared to those discharged on
day three or four postoperative [4]. The rate of serious
adverse events in the inpatient group is expected to be
greater than 5 % [20]. To define a non-inferiority margin
we agreed that no more than a 5 % increase in the risk
of serious adverse event (risk difference ≥ 6% favouring
inpatient care) was acceptable. If the risk in the inpatient
group ranges between five to 8 % and there is truly no
difference in risk of serious adverse event between the
groups, then a maximum of 506 patients are required to
be 80% certain that the upper limit of a one-sided 95%
confidence interval will exclude a difference in favour of
the inpatient group of more than 6 % [21]. Given that
the primary outcome is being measured at 30-days post-
operative, we anticipate a low lost-to-follow-up rate. Pre-
vious studies conducted at the lead study site in similar
patients demonstrate loss to follow up rates less than 1
% for the first 30 days. Therefore, to account for a poten-
tial 1 % dropout rate we inflated our sample size to 511.
Plan for statistical analysis
We will present the incidence of serious adverse events
by group at 30 days postoperative and calculate a risk
difference and relative risk with 95% confidence intervals
around the estimates. The mean and standard deviation
for all continuous outcomes (Satisfaction, WOMAC, SF-
12, HHS, Pain NRS, and CAS) will be calculated for each
group at each time point and calculate the mean
between-group difference with 95% confidence interval.
Linear mixed models, using a covariance structure that
allows for correlations between measurements to decline
as they are further apart in time will be used to evaluate
improvements in function after surgery since this pro-
vides a powerful approach to analyze complex longitu-
dinal data while controlling for important covariates
such as gender, comorbidities, age and surgeon/site. All
data will be analyzed according to the intention-to-treat
principle with an as treated analysis also performed.
We will conduct a cost-effectiveness analysis from
both a Canadian healthcare payer and societal perspec-
tive using the incidence of adverse events as our effect-
iveness outcome to estimate cost-effectiveness at 3
months postoperative. We will determine cost-
effectiveness using the net benefit regression (NBR)
framework to estimate the incremental net benefit (INB)
of outpatient arthroplasty [22]. An intervention is con-
sidered to be cost-effective if the INB is greater than
zero. NBR also provides a means to adjust for potentially
confounding factors and therefore allows greater statis-
tical efficiency and a more precise estimate of the INB.
To characterize the statistical uncertainty around our es-
timate of INB we will calculate 95% confidence intervals,
and a cost-effectiveness acceptability curve [23].
Patient and public involvement
Patients or the public were not involved in the design, or
conduct, or reporting, or dissemination plans of our
research.
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Data collection methods
Follow-up assessments for this study coincide with the
standard of care follow-up schedule for the surgeons at
our centre. During each visit, the research assistant will
administer the questionnaires to the participants and en-
sure they are completed. Alternatively, participants are
also given the option to complete questionnaires online by
directly accessing the electronic data capture (EDC) sys-
tem (Empower Health Research). The HHS will be com-
pleted by the treating surgeon at the three-month visit.
Data management
Participants have the option to complete questionnaires
either in hard copy or using the EDC system (Empower
Health Research).
Discussion
This protocol is for a multi-centered randomized con-
trolled trial to assess the safety and cost-effectiveness of
outpatient total hip arthroplasty compared to standard
inpatient care. There is currently a lack of high-quality
studies evaluating the safety and effectiveness of out-
patient THA. Most studies that have assessed safety have
used US national databases [24–29] or observational co-
hort designs [30–33] with only one published random-
ized trial [34]. Previous prospective studies have also
been underpowered to detect differences in complication
rates between outpatient and inpatient care groups. Due
to the already low rates of serious adverse events after
THA, reported from 3.8% up to 8.6% in the literature,
[20, 35, 36] sample sizes must be sufficiently large to in-
clude a sufficient number of events to support clinical
conclusions. Our protocol will be the first adequately
powered prospective study to evaluate the safety of out-
patient THA.
One strength of our study protocol is the use of a modi-
fied Zelen consent model [19], as one of the difficulties
with assessing outpatient discharge in comparison with
standard inpatient care is potential patient biases. This de-
sign allows us to avoid these biases as patients with a
strong preference for either group are not made aware of
the alternative intervention. A weakness of the random-
ized trial by Goyal et al. (2017) was the lack of blinding
which led to a significant number of crossovers due to
personal preference [34]. Our use of a modified Zelen
consent model [19] should help to address this issue and
reduce the number of crossovers in our study. Future
studies looking to evaluate outpatient THA should also
consider use of this design to strengthen their conclusions
and reduce patient crossover.
Our study will be the first to perform a full economic
evaluation in conjunction with a large randomized trial
and will use both healthcare payer and societal perspec-
tives. No full economic evaluations have been published
to compare outpatient to standard inpatient care thus
far. This is an important gap in the literature as inter-
national health economic guidelines suggest policy and
clinical decisions should be supported by evidence pro-
duced when cost is evaluated simultaneously with effect
in a full economic evaluation [37, 38]. Previous studies
have evaluated cost alone [5, 6] and none in conjunction
with a prospective trial. These studies have also only in-
cluded direct costs associated with the procedures and
hospital costs. Including a broader perspective and in-
corporating indirect costs such as time off work and
caregiver assistance are important to consider, ensuring
that costs possibly saved from reduced hospital stays are
not shifted elsewhere in the recovery pathway. To truly
know whether outpatient THA is less costly than in-
patient care, as the literature currently suggests [5, 6],
broader perspectives (ie. healthcare payer and societal)
should be assessed. The use of multiple perspectives also
helps to broaden the interpretability of study results and
is recommended by international health economic
guidelines [37]. The importance of costing perspective is
highlighted in a paper by Primeau et al. (2019) where
the conclusions of the study changed depending on the
perspective used [39].
Our protocol hopes to address several gaps in the
current literature with a large and adequately powered
sample size to assess safety, the use of blinding with a
modified Zelen consent model [19], and assessing costs
in conjunction with a prospective randomized trial for a
full economic evaluation. Conclusions from our study
should help to inform clinical decision making in the
use of outpatient care programs in standard practice for
THA. Recruitment for the study is currently ongoing.
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